Search

everythinglearnresearchcommunity

for

Search:↓

Alfredo Rebora suggested a new, easier way to classify hair loss in Telogen Effluvium, adding a type possibly related to autoimmune diseases.

The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.

Hair loss in Telogen effluvium is often chronic, linked to stress, and lacks a confirmed treatment, but topical corticosteroids may be used.

Alfredo Rebora suggests a simpler classification for hair loss and a new test for easier diagnosis.

People with hair loss conditions may also have thyroid disorders, but more research is needed to understand the connection.

Auto-antibody testing is a useful but not definitive tool in diagnosing interstitial lung diseases, and using a specific algorithm could make testing more cost-effective.

Scalp biopsies from dermatomyositis patients show chronic hair loss without scarring, with mucin and blood vessel changes being very common.

The new hair loss treatment kit was safe and improved hair growth without any adverse effects.

Different hair diseases affect people during childbearing years, with treatments ranging from medication to psychological support.

Steroid treatment improved both gut and nerve symptoms in a man with Cronkhite–Canada syndrome.

A 68-year-old woman with lupus and blood disorders improved after increased steroids and immunoglobulin treatment.

The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

There is no standard treatment for the rare Cronkhite–Canada syndrome, which can be fatal and lead to cancer.

The document concludes that managing skin conditions during pregnancy is important and requires specialized care.

Autoimmune liver diseases are likely linked to certain skin conditions like vitiligo and psoriasis.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.

Blocking interferon-gamma might help treat various autoimmune diseases.

A woman lost over 80% of her hair due to a condition called telogen effluvium after having COVID-19.

Some skin diseases and their treatments can negatively affect male fertility.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Early diagnosis, intensive therapy, and careful follow-up are crucial for managing overlapping TTP and SLE.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

Levothyroxine is less effective in men with early-onset male-pattern baldness.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

Increased mucin in the skin might indicate lupus in patients with hair loss, but more research is needed.

The paper suggests improving diagnosis and treatment of telogen effluvium but does not recommend a new classification system.

Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.

The document concludes that permanent hair loss conditions are complex, require early specific treatments, and "secondary permanent alopecias" might be a more accurate term than "secondary cicatricial alopecia."